Renaissance Technologies’s TG Therapeutics TGTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $11.3M | Buy |
+340,900
| New | +$10.2M | 0.02% | 913 |
|
|
2025
Q2 | – | Sell |
-168,594
| Closed | -$6.65M | – | 3895 |
|
|
2025
Q1 | $6.65M | Buy |
+168,594
| New | +$5.67M | 0.01% | 1245 |
|
|
2024
Q3 | – | Sell |
-309,371
| Closed | -$5.5M | – | 3883 |
|
|
2024
Q2 | $5.5M | Sell |
309,371
-531,229
| -63% | -$8.48M | 0.01% | 1233 |
|
|
2024
Q1 | $12.8M | Buy |
840,600
+1,400
| +0.2% | +$22.3K | 0.02% | 861 |
|
|
2023
Q4 | $14.3M | Sell |
839,200
-537,262
| -39% | -$6.24M | 0.02% | 774 |
|
|
2023
Q3 | $11.5M | Buy |
1,376,462
+840,262
| +157% | +$11.7M | 0.02% | 844 |
|
|
2023
Q2 | $13.3M | Buy |
+536,200
| New | +$13.8M | 0.02% | 882 |
|
|
2023
Q1 | – | Sell |
-99,100
| Closed | -$1.17M | – | 4400 |
|
|
2022
Q4 | $1.17M | Sell |
99,100
-80,100
| -45% | -$581K | ﹤0.01% | 2436 |
|
|
2022
Q3 | $1.06M | Sell |
179,200
-1,001,900
| -85% | -$6.57M | ﹤0.01% | 2461 |
|
|
2022
Q2 | $5.02M | Buy |
1,181,100
+983,500
| +498% | +$6.14M | 0.01% | 1553 |
|
|
2022
Q1 | $1.88M | Sell |
197,600
-51,600
| -21% | -$597K | ﹤0.01% | 2277 |
|
|
2021
Q4 | $4.74M | Buy |
+249,200
| New | +$6.47M | 0.01% | 1575 |
|
|
2021
Q3 | – | Sell |
-145,800
| Closed | -$5.66M | – | 3836 |
|
|
2021
Q2 | $5.66M | Buy |
145,800
+11,800
| +9% | +$463K | 0.01% | 1559 |
|
|
2021
Q1 | $6.46M | Sell |
134,000
-234,000
| -64% | -$11.2M | 0.01% | 1494 |
|
|
2020
Q4 | $19.1M | Buy |
368,000
+269,400
| +273% | +$9.1M | 0.02% | 781 |
|
|
2020
Q3 | $2.64M | Sell |
98,600
-1,056,800
| -91% | -$24.3M | ﹤0.01% | 1963 |
|
|
2020
Q2 | $22.5M | Buy |
1,155,400
+643,600
| +126% | +$10.4M | 0.02% | 753 |
|
|
2020
Q1 | $5.04M | Sell |
511,800
-667,700
| -57% | -$8.43M | ﹤0.01% | 1562 |
|
|
2019
Q4 | $13.1M | Buy |
1,179,500
+1,070,706
| +984% | +$8.14M | 0.01% | 1273 |
|
|
2019
Q3 | $611K | Sell |
108,794
-51,706
| -32% | -$360K | ﹤0.01% | 2794 |
|
|
2019
Q2 | $1.39M | Buy |
160,500
+114,400
| +248% | +$865K | ﹤0.01% | 2538 |
|
|
2019
Q1 | $371K | Sell |
46,100
-829,800
| -95% | -$4.48M | ﹤0.01% | 3033 |
|
|
2018
Q4 | $3.59M | Buy |
875,900
+523,400
| +148% | +$2.6M | ﹤0.01% | 1936 |
|
|
2018
Q3 | $1.97M | Buy |
+352,500
| New | +$4.03M | ﹤0.01% | 2279 |
|
|
2015
Q2 | – | Sell |
-19,399
| Closed | -$300K | – | 3382 |
|
|
2015
Q1 | $300K | Sell |
19,399
-138,482
| -88% | -$2.1M | ﹤0.01% | 2768 |
|
|
2014
Q4 | $2.5M | Buy |
157,881
+146,682
| +1,310% | +$1.91M | 0.01% | 1678 |
|
|
2014
Q3 | $119K | Buy |
+11,199
| New | +$104K | ﹤0.01% | 2638 |
|
Other funds holding TGTX
VPM
VCM
SCM
CAM
Renaissance Technologies's TGTX Position: Q1 2026 in Review
Renaissance Technologies opened a new position in TG Therapeutics (TGTX) in Q1 2026: 340,900 shares worth $11.3M. The stake represents 0.02% of the portfolio and ranks #913 among its holdings. This is a return to the name: Renaissance Technologies previously reported a position in TGTX as recently as Q1 2025.
Renaissance Technologies first reported a position in TGTX in Q3 2014 and has held it in 27 quarters since. The position peaked at $22.5M in Q2 2020. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.
- Renaissance Technologies held 340,900 shares of TG Therapeutics worth $11.3M as of Q1 2026.
- TG Therapeutics was a new Renaissance Technologies position in Q1 2026.
- TG Therapeutics made up 0.02% of Renaissance Technologies's portfolio in Q1 2026, its #913 holding.
- Renaissance Technologies first reported a position in TG Therapeutics in Q3 2014 and has held it in 27 quarters since.
- Renaissance Technologies's TG Therapeutics position peaked at $22.5M in Q2 2020.
- 363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.
Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.